We'll know more about the company's medium-term prospects by the end of the year.

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

CRISPR Therapeutics (CRSP) stock dropped 11% after missing Q1 estimates badly. Regeneron's free gene therapy approval adds ...

The Pairwise Fulcrum® platform includes proprietary gene editing tools, enzymes, and trait libraries that enable precise genetic changes, unlocking plants’ inherent potential and significantly ...

The gene editing treatment targets the relatively common 1717-1G>A splicing mutation, which does not respond to many current CF therapies.

Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...

Genome‑wide CRISPR screens in primary human T cells reveal human genes that promote or block HIV infection, uncovering potent ...

There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...

Researchers announced two major CRISPR breakthroughs: a method to boost production of virus-like particles for gene delivery, and a ThermoCas9 enzyme that can distinguish cancer cells from healthy ...

Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...

View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.

Qatar has taken a landmark step in precision medicine after Sidra Medicine became the first hospital in the country — and one ...